Circulating blood cells, and cell-derived microvesicles, are emerging as pragmatic delivery systems that can smartly complement the already existing nanotherapeutic platforms evaluated to treat or diagnose diseases. The valuable distinctive features of circulatory cells over synthetic nanocarriers encompass their biological origin which confers immune transparence, known biodegradability, high drug loading, relatively long half-life and a targeting capacity associated with their physiological surface functionality. Absence of nuclei in red blood cells and platelets provides further rationale for their use as cargo vehicles for nucleotoxic agents. Ongoing developments in cell-based and cell-inspired nanotherapies can move drug delivery into reachable frontiers and exhibit high potentiality for translatability into clinical use.

循环血细胞和细胞衍生的微囊正在作为实用的递送系统出现，可以智能地补充已经评估用于治疗或诊断疾病的现有纳米治疗平台。循环细胞在合成纳米载体上的宝贵独特特征包括赋予免疫透明性的生物起源，已知的生物可降解性，高载药量，相对长的半衰期以及与其生理表面功能相关的靶向能力。红细胞和血小板中无核为它们用作核毒性剂的运载体提供了进一步的理由。基于细胞和细胞启发的纳米疗法的不断发展可以将药物输送转移到可及的领域，并具有可转换为临床用途的高潜力。